Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The primary objective was to determine superiority of dulaglutide 1.5 mg versus placebo in HbA1c change at 26 weeks. RESEARCH DESIGN AND METHODS: This 52-week, multicenter, parallel-arm study (primary end point: 26 weeks) randomized patients (2:2:2:1) to dulaglutide 1.5 mg, dulaglutide 0.75 mg, exenatide 10 μg, or placebo (placebo-controlled period: 26 weeks). Patients were treated with metformin (1,500–3,000 mg) and pioglitazone (30–45 mg). Mean baseline HbA1c was 8.1% (65 mmol/mol). RESULTS: Least squares mean ± SE HbA1c change from baseline to the primary end point was −1.51 ± 0.06% (−16.5 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, −1.30 ± 0.06% (−14.2 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, −0.99 ± 0.06% (−10.8 ± 0.7 mmol/mol) for exenatide, and −0.46 ± 0.08% (−5.0 ± 0.9 mmol/mol) for placebo. Both dulaglutide doses were superior to placebo at 26 weeks (both adjusted one-sided P < 0.001) and exenatide at 26 and 52 weeks (both adjusted one-sided P < 0.001). Greater percentages of patients reached HbA1c targets with dulaglutide 1.5 mg and 0.75 mg than with placebo and exenatide (all P < 0.001). At 26 and 52 weeks, total hypoglycemia incidence was lower in patients receiving dulaglutide 1.5 mg than in those receiving exenatide; no dulaglutide-treated patients reported severe hypoglycemia. The most common gastrointestinal adverse events for dulaglutide were nausea, vomiting, and diarrhea. Events were mostly mild to moderate and transient. CONCLUSIONS: Both once-weekly dulaglutide doses demonstrated superior glycemic control versus placebo and exenatide with an acceptable tolerability and safety profile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another analog of human of GLP-1, but in once weekly administration, was similarly found to be superior to exenatide twice daily in reducing HbA1C, −1.51% vs. −0.99%.18”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [18]
In the citing paper
“The most common adverse events (AEs) reported with GLP-1RAs were gastrointestinal disorders, such as nausea, diarrhea, vomiting, and abdominal pain, etc (7–9).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [8]
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“American Indian 40 (14) 37 (13) 38 (14) 20 (14)”
ResultBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Cited by
Items 101–200 of 396
Matza, L. S., Boye, K. S., Stewart, K. D., Coyne, K. S., Wullenweber, P. K., Cutts, K. N., Jordan, J. B., Wang, Q., Yu, M., Currie, B. M., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13902 · Cited by 46
Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 48
Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., & Juneja, R. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12687 · Cited by 46
Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-200 · Cited by 45
McAdam-Marx, C., White, K. N., & Gurgle, H. E. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83088 · Cited by 48
Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management
Chun, J. H., & Butts, A. (2020) · JAAPA · doi:10.1097/01.jaa.0000669456.13763.bd · Cited by 45
Zhang, L., Zhang, M., Zhang, Y., & Tong, N. (2016) · Scientific Reports · doi:10.1038/srep18904 · Cited by 43
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 57
GLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
What have we learnt from “real world” data, observational studies and meta‐analyses
Chatterjee, S., Davies, M. J., & Khunti, K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13178 · Cited by 43
Chen, Y. H., Huang, C., Cho, Y. M., Li, P., Gu, L., Wang, F., Yang, J., & Wang, W. Q. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13340 · Cited by 43
Dulaglutide for the treatment of type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1296131 · Cited by 48
Xia, L., Shen, T., Dong, W., Su, F., Wang, J., Wang, Q., Niu, S., & Fang, Y. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108904 · Cited by 40
Clemens, K. K., Ernst, J., Khan, T., Reichert, S., Khan, M. Q., LaPier, H., Chiu, M., Stranges, S., Sahi, G., Castrillon-Ramirez, F., et al. (2023) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.023 · Cited by 40
Anti-Obesity Drug Delivery Systems: Recent Progress and Challenges
Ashour, M. M., Mabrouk, M., Aboelnasr, M. A., Beherei, H. H., Tohamy, K. M., & Das, D. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112635 · Cited by 45
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
Waldrop, G., Zhong, J.-X., Peters, M., Goud, A., Chen, Y.-H., Davis, S. N., Mukherjee, B., & Rajagopalan, S. (2018) · Journal of diabetes and its complications · doi:10.1016/j.jdiacomp.2016.08.018 · Cited by 35
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Borner, T., Workinger, J. L., Tinsley, I. C., Fortin, S. M., Stein, L. M., Chepurny, O. G., Holz, G. G., Wierzba, A. J., Gryko, D., Nexø, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107768 · Cited by 39
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
Orandi, B. J., Chen, Y., Li, Y., Charyton, D., Lentine, K. L., Lee, B. P., Ali, N., DeMarco, M. P., Weintraub, M. A., Bae, S., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000750 · Cited by 38
Wang, T., Gou, Z., Wang, F., Ma, M., & Zhai, S.-D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103798 · Cited by 37
Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis
Lee, C. M. Y., Woodward, M., & Colagiuri, S. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.037 · Cited by 37
Wysham, C., Rosenstock, J., Vetter, M. L., Dong, F., Öhman, P., & Iqbal, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13056 · Cited by 38
Self-citationMirabelli, M., Chiefari, E., Tocci, V., Caroleo, P., Giuliano, S., Greco, E., Luque, R. M., Puccio, L., Foti, D. P., Aversa, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050985 · Cited by 37
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Reaney, M. D., Yu, M., Lakshmanan, M. C., Pechtner, V., & Brunt, K. V. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12527 · Cited by 36
Self-citationIncretin-Based Therapy for Diabetes
Waldrop, G. E., Zhong, J., Peters, M. C., & Rajagopalan, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.058 · Cited by 39
Umpierrez, G. E., Pantalone, K. M., Kwan, A. Y. M., Zimmermann, A. G., Zhang, N., & Fernández Landó, L. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12660 · Cited by 36
Nauck, M. A., Frossard, J.-L., Barkin, J. S., Anglin, G., Hensley, I. E., Harper, K. D., & Milicevic, Z. (2017) · Diabetes Care · doi:10.2337/dc16-0984 · Cited by 36
Babenko, A. Y., Savitskaya, D. A., Kononova, Y. A., Trofimova, A. Y., Simanenkova, A. V., Vasilyeva, E. Y., & Shlyakhto, E. V. (2019) · Journal of Diabetes Research · doi:10.1155/2019/1365162 · Cited by 35
PEREZ-MONTES DE OCA, A., PELLITERO, S., & PUIG-DOMINGO, M. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03369-6 · Cited by 36
Gupta, A., Jelinek, H. F., & Al-Aubaidy, H. A. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.09.003 · Cited by 40
Bariatric surgery – time to replace with GLP-1?
Webb, D.-L., Abrahamsson, N., Sundbom, M., & Hellström, P. M. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1293154 · Cited by 35
Pharmacotherapy of ‘treatment resistant’ type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1297424 · Cited by 40
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Milicevic, Z., Anglin, G., Harper, K., Konrad, R. J., Skrivanek, Z., Glaesner, W., Karanikas, C. A., & Mace, K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12640 · Cited by 32
Cimmaruta, D., Maiorino, M., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221402 · Cited by 33
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
Alkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
King, A., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0027 · Cited by 34
Sloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31
Morieri, M. L., Rigato, M., Frison, V., Simioni, N., D'Ambrosio, M., Tadiotto, F., Paccagnella, A., Lapolla, A., Avogaro, A., & Fadini, G. P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154190 · Cited by 31
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation
Yu, M. B., Xie, J., Landó, L. F., Kabul, S., & Swindle, R. W. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.11.017 · Cited by 32
The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs
Rodbard, H. W. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0103 · Cited by 30
Kuritzky, L., Umpierrez, G., Ekoé, J. M., Mancillas-Adame, L., & Landó, L. F. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2821 · Cited by 29
Emoto, M., Terauchi, Y., Ozeki, A., Oura, T., Takeuchi, M., & Imaoka, T. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0401 · Cited by 29
Dulaglutide: A Review in Type 2 Diabetes
Burness, C. B., & Scott, L. J. (2015) · BioDrugs · doi:10.1007/s40259-015-0143-4 · Cited by 33
Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist.
Smith, L. L., Mosley, J., Parke, C. K., Brown, J., Ls, B., & Phan, L. D. (2016) · PubMed · Cited by 42
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong, B., Yao, Z., Zhou, C., Wang, W., Sun, L., & Han, J. D. J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116342 · Cited by 29
Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome
Chatterjee, S., Ghosal, S., & Chatterjee, S. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i18.441 · Cited by 30
Matza, L. S., Boye, K. S., Currie, B. M., Paczkowski, R., Landó, L. F., Mody, R., & Jordan, J. B. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1465903 · Cited by 28
Orme, M., Nguyen, H., Lu, J., & Thomas, S. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s116810 · Cited by 27
Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
Inia, J. A., Stokman, G., Morrison, M. C., Worms, N., Verschuren, L., Caspers, M. P. M., Menke, A. L., Petitjean, L., Chen, L., Petitjean, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108494 · Cited by 33
Yu, M., Brunt, K. V., Varnado, O. J., & Boye, K. S. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12624 · Cited by 31
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes
Scheen, A. J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1141046 · Cited by 28
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Morieri, M. L., Avogaro, A., & Fadini, G. P. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s216054 · Cited by 25
Pratley, R. E., Aroda, V. R., Catarig, A., Lingvay, I., Lüdemann, J., Yildirim, E., & Viljoen, A. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037883 · Cited by 31
Pharmacologic Treatment of Type 2 Diabetes: Injectable Medications
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573010 · Cited by 32
Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes
Berra, C., Resi, V., Mirani, M., Folini, L., Rossi, A., Solerte, S. B., & Fiorina, P. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104996 · Cited by 27
Kugler, A. J., & Thiman, M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s134960 · Cited by 27
Wang, J., Li, H.-Q., Xu, X.-H., Kong, X.-C., Sun, R., Jing, T., Ye, L., Su, X.-F., & Ma, J.-H. (2019) · BioMed Research International · doi:10.1155/2019/2682657 · Cited by 23
de Wit, H. M., Groen, M. T., Rovers, M. M., & Tack, C. J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12925 · Cited by 29
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Austin, G. O., & Tomás, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1170181 · Cited by 25
Liu, Y., He, L., Han, S., Ping, F., Li, W., Xu, L., Zhang, H., & Li, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039446 · Cited by 27
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 26
Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
Edwards, K. L., & Minze, M. G. (2015) · Core evidence · doi:10.2147/ce.s55944 · Cited by 24
Salmen, T., Șerbănoiu, L. I., Bica, I.-C., Serafinceanu, C., Muzurović, E. M., Janež, A., Busnatu, Ș., Banach, M., Rizvi, A. A., Rizzo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119760 · Cited by 24
Xue, X., Ren, Z., Zhang, A., Yang, Q., Zhang, W., & Liu, F. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12847 · Cited by 27
Han, J. D. J., Chen, X., Wang, Y., Fei, Y., Zhou, F. L., Zhang, Y., Liu, L., Si, P., & Fu, J. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.06.132 · Cited by 23
Boye, K. S., Matza, L. S., Stewart, K. D., Jordan, J. B., Biricolti, G., Santo, S. D., Perez‐Nieves, M., Federici, M. O., Gentilella, R., Losi, S., et al. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1609482 · Cited by 23
Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers
Anderson, J. E., Thieu, V. T., Boye, K. S., Hietpas, R. T., & García‐Pérez, L. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1218260 · Cited by 23
Li, H., Xu, X., Wang, J., Kong, X., Chen, M., Jing, T., Zhang, Z., Yin, G., Liu, X., Hu, Y., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/6423987 · Cited by 21
Anson, M., Henney, A. E., Zhao, S. S., Hernández, G., Lip, G. Y. H., Cuthbertson, D. J., Nabrdalik, K., & Alam, U. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15576 · Cited by 27
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
Gurung, T., Waugh, N. R., O’Hare, J. P., & Shyangdan, D. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s34418 · Cited by 22
Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 24
Mathieu, C., Prato, S. D., Botros, F. T., Thieu, V. T., Pavo, I. J., Jia, N., Haupt, A., Karanikas, C. A., & García‐Pérez, L. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13313 · Cited by 24
Billings, L. K., Handelsman, Y., HEILE, M. K., Schneider, D., & Wyne, K. L. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s30 · Cited by 31
Bain, E. K., & Bain, S. C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 20
Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus
Lee, J., Kim, R., Kim, M.-H., Lee, S.-H., Cho, J.-H., Lee, J. M., Jang, S.-A., & Kim, H.-S. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.006 · Cited by 20
Kang, Y. M., Punov, V., Lim, S., & Nauck, M. A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16398 · Cited by 20
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Trials · doi:10.1186/s13063-023-07164-9 · Cited by 20
Kaneko, S., Oura, T., Matsui, A., Shingaki, T., & Takeuchi, M. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej17-0189 · Cited by 20
Saulsberry, W. J., Coleman, C. I., Mearns, E. S., Zaccaro, E., Doleh, Y., & Sobieraj, D. M. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12698 · Cited by 23
Lindamood, C., & Taylor, J. R. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.01.003 · Cited by 22
Chou, C., Chang, Y., Yang, J.-L., Wang, J., Lee, T.-E., Wang, R., & Hung, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16101-1 · Cited by 20
Defining estimands using a mix of strategies to handle intercurrent events in clinical trials
Qu, Y., Shurzinske, L., & Sethuraman, S. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2078 · Cited by 25
Van, J. T., Frías, J. P., Bonora, E., Raha, S., Meyer, J., Jung, H., Cox, D., Кониг, М., Peleshok, J. C., & Bethel, M. A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01140-9 · Cited by 20
Wysham, C., Guerci, B., D’Alessio, D. A., Jia, N., & Botros, F. T. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12702 · Cited by 20
Self-citationPantalone, K. M., Patel, H., Yu, M. B., & Landó, L. F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13252 · Cited by 20
Predicting responsiveness to GLP-1 pathway drugs using real-world data
Zhu, X., Fowler, M. J., Wells, Q. S., Stafford, J. M., & GANNON, M. A. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01798-9 · Cited by 22
Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know
Chan, P. Y. W., Mika, A. P., Martin, J. R., & Wilson, J. M. (2024) · JBJS Reviews · doi:10.2106/jbjs.rvw.23.00167 · Cited by 21
Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment
Deng, W.-Y., Zhao, Z., Zou, T., Kuang, T.-D., & Wang, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s421527 · Cited by 23
Giorgino, F., Bonadonna, R., Gentile, S., Vettor, R., & Pozzilli, P. (2016) · Diabetes/Metabolism Research Reviews · doi:10.1002/dmrr.2775 · Cited by 17
Le point sur un médicament : le dulaglutide (Trulicity®)
Bauduceau, B. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30025-2 · Cited by 19
Mari, A., Prato, S. D., Ludvik, B. H., Miličević, Z., de la Peña, A., Shurzinske, L., Karanikas, C. A., & Pechtner, V. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12671 · Cited by 18
Lally, J., Loughlin, A. O., Stubbs, B., Guérandel, A., O'Shea, D. B., & Gaughran, F. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445968 · Cited by 18
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Metadata
- Authors
- Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M.
- Affiliations
- Redwood Clinic, Spokane, WA
- Texas Diabetes & Endocrinology (US)
- University of Hawaiʻi at Mānoa (US)
- American Telemedicine Center of Puerto Rico, San Juan, PR
- University Hospital Autonomous University of Nuevo León, Monterrey, Mexico
- Eli Lilly (United States) (US)
- Corresponding author
- Lakshmanan, Mark
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-07-12
- Volume
- 37
- Issue
- 8
- Pages
- 2159-2167
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2104252114
- Cited by
- 396
- References
- 24
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 26 · 2023: 27 · 2022: 15 · 2021: 25 · 2020: 31 · 2019: 31 · 2018: 34 · 2017: 38 · 2016: 47 · 2015: 44 · 2014: 10
- FWCI
- 37.26
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-10-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- dulaglutide, exenatide, type 2 diabetes, GLP-1 receptor agonists, pioglitazone, metformin, HbA1c, glycemic control, hypoglycemia, drug safety, combination therapy, dose comparison, HbA1c targets, weight gain, adverse events
- MeSH terms
- Pioglitazone, Exenatide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Middle Aged, Peptides, Recombinant Fusion Proteins, Venoms, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.